Telehealth firm Hims & Hers Health reported a first‑quarter loss of $92.1 million, or 40 cents per share, reversing a profit of $49.5 million a year earlier. Revenue grew modestly, but rising costs in operations, technology and G&A erased the upside. Analysts had expected a modest 3‑cent profit, leaving investors disappointed in the broader digital health market.

Shares tumbled 9.5% in after‑hours trading, settling at $26.37, and remain down more than 10% year‑to‑date. The downgrade reflects management’s decision to slash the full‑year profit outlook as the company pours additional capital into product development and platform upgrades. Investors now weigh growth ambitions against an expanding cost base in a competitive telemedicine sector.

Quarterly revenue rose year‑over‑year, signaling continued consumer demand for remote prescribing and wellness services. However, the surge in operating expenses—particularly technology spend aimed at scaling AI‑driven diagnostics—outpaced top‑line growth. The earnings miss underscores the challenge of balancing aggressive expansion with profitability in a market still defining sustainable unit economics for both established players and newcomers.

Management’s revised guidance will likely pressure valuation multiples as analysts reassess cash‑burn timelines. Companies with similar cost structures may see comparable stock reactions, prompting a closer look at expense discipline across the telehealth subsector. The episode serves as a reminder that top‑line growth alone cannot sustain investor confidence without clear pathways to margin improvement significantly.